New drugs for early Alzheimer’s disease may allow people to live without help for up to 39 additional months, a new study estimates. But experts urge caution.

The FDA will decide on subcutaneous maintenance dosing of lecanemab by August. Some patients are opting for donanemab because that treatment has a set end date. Reaction from clinicians was varied, ...

Until recently, available treatments primarily managed symptoms with only modest effects. New drugs, such as lecanemab and donanemab, have shown promise in slowing the progression of Alzheimer’s ...

Recently, lecanemab and donanemab have been shown to reduce the build-up in the brain of amyloid plaques -- a key characteristic of Alzheimer's disease -- and to slow down progression of the ...

Recently, lecanemab and donanemab have been shown to reduce the build-up in the brain of amyloid plaques – a key characteristic of Alzheimer's disease – and to slow down progression of the ...

The reasons for this stagnation have been discussed endlessly here on Think. In short, a combination of cyclical and structural headwinds has paralysed the economy. While cyclical headwinds like high ...